Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Association of FGFR4 genetic polymorphisms with prostate cancer risk and prognosis

Prostate Cancer and Prostatic Diseases volume 12, pages 192–197 (2009)Cite this article

Abstract

The fibroblast growth factor receptor 4 (FGFR4) is thought to be involved in many critical cellular processes and has been associated with prostate cancer risk. Four single nucleotide polymorphisms (SNPs) within or near FGFR4 were analyzed in a population-based study of 1458 prostate cancer patients and 1352 age-matched controls. We found no evidence to suggest that any of the FGFR4 SNP genotypes were associated with prostate cancer risk or with disease aggressiveness, Gleason score or stage. A weak association was seen between rs351855 and prostate cancer-specific mortality. Subset analysis of cases that had undergone radical prostatectomy revealed an association between rs351855 and prostate cancer risk. Although our results confirm an association between FGFR4 and prostate cancer risk in radical prostatectomy cases, they suggest that the role of FGFR4 in disease risk and outcomes at a population-based level appears to be minor.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Ornitz DM, Xu J, Colvin JS, McEwen DG, MacArthur CA, Coulier F et al. Receptor specificity of the fibroblast growth factor family. J Biol Chem 1996; 271: 15292–15297.

    Article  CAS  PubMed  Google Scholar 

  2. Schlessinger J . Cell signaling by receptor tyrosine kinases. Cell 2000; 103: 211–225.

    Article  CAS  PubMed  Google Scholar 

  3. Acevedo VD, Gangula RD, Freeman KW, Li R, Zhang Y, Wang F et al. Inducible FGFR-1 activation leads to irreversible prostate adenocarcinoma and an epithelial-to-mesenchymal transition. Cancer Cell 2007; 12: 559–571.

    Article  CAS  PubMed  Google Scholar 

  4. Dorkin TJ, Robinson MC, Marsh C, Bjartell A, Neal DE, Leung HY . FGF8 over-expression in prostate cancer is associated with decreased patient survival and persists in androgen independent disease. Oncogene 1999; 18: 2755–2761.

    Article  CAS  PubMed  Google Scholar 

  5. Freeman KW, Gangula RD, Welm BE, Ozen M, Foster BA, Rosen JM et al. Conditional activation of fibroblast growth factor receptor (FGFR) 1, but not FGFR2, in prostate cancer cells leads to increased osteopontin induction, extracellular signal-regulated kinase activation, and in vivo proliferation. Cancer Res 2003; 63: 6237–6243.

    CAS  PubMed  Google Scholar 

  6. Freeman KW, Welm BE, Gangula RD, Rosen JM, Ittmann M, Greenberg NM et al. Inducible prostate intraepithelial neoplasia with reversible hyperplasia in conditional FGFR1-expressing mice. Cancer Res 2003; 63: 8256–8263.

    CAS  PubMed  Google Scholar 

  7. Gowardhan B, Douglas DA, Mathers ME, McKie AB, McCracken SR, Robson CN et al. Evaluation of the fibroblast growth factor system as a potential target for therapy in human prostate cancer. Br J Cancer 2005; 92: 320–327.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Kwabi-Addo B, Wang J, Erdem H, Vaid A, Castro P, Ayala G et al. The expression of Sprouty1, an inhibitor of fibroblast growth factor signal transduction, is decreased in human prostate cancer. Cancer Res 2004; 64: 4728–4735.

    Article  CAS  PubMed  Google Scholar 

  9. Leung HY, Dickson C, Robson CN, Neal DE . Over-expression of fibroblast growth factor-8 in human prostate cancer. Oncogene 1996; 12: 1833–1835.

    CAS  PubMed  Google Scholar 

  10. Memarzadeh S, Xin L, Mulholland DJ, Mansukhani A, Wu H, Teitell MA et al. Enhanced paracrine FGF10 expression promotes formation of multifocal prostate adenocarcinoma and an increase in epithelial androgen receptor. Cancer Cell 2007; 12: 572–585.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Ozen M, Giri D, Ropiquet F, Mansukhani A, Ittmann M . Role of fibroblast growth factor receptor signaling in prostate cancer cell survival. J Natl Cancer Inst 2001; 93: 1783–1790.

    Article  CAS  PubMed  Google Scholar 

  12. Ropiquet F, Giri D, Kwabi-Addo B, Mansukhani A, Ittmann M . Increased expression of fibroblast growth factor 6 in human prostatic intraepithelial neoplasia and prostate cancer. Cancer Res 2000; 60: 4245–4250.

    CAS  PubMed  Google Scholar 

  13. Sahadevan K, Darby S, Leung HY, Mathers ME, Robson CN, Gnanapragasam VJ . Selective over-expression of fibroblast growth factor receptors 1 and 4 in clinical prostate cancer. J Pathol 2007; 213: 82–90.

    Article  CAS  PubMed  Google Scholar 

  14. Tanaka A, Furuya A, Yamasaki M, Hanai N, Kuriki K, Kamiakito T et al. High frequency of fibroblast growth factor (FGF) 8 expression in clinical prostate cancers and breast tissues, immunohistochemically demonstrated by a newly established neutralizing monoclonal antibody against FGF 8. Cancer Res 1998; 58: 2053–2056.

    CAS  PubMed  Google Scholar 

  15. Wang J, Cai Y, Penland R, Chauhan S, Miesfeld RL, Ittmann M . Increased expression of the metastasis-associated gene Ehm2 in prostate cancer. Prostate 2006; 66: 1641–1652.

    Article  CAS  PubMed  Google Scholar 

  16. Wang J, Stockton DW, Ittmann M . The fibroblast growth factor receptor-4 Arg388 allele is associated with prostate cancer initiation and progression. Clin Cancer Res 2004; 10 (18 Pt 1): 6169–6178.

    Article  CAS  PubMed  Google Scholar 

  17. Bange J, Prechtl D, Cheburkin Y, Specht K, Harbeck N, Schmitt M et al. Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele. Cancer Res 2002; 62: 840–847.

    CAS  PubMed  Google Scholar 

  18. Matakidou A, El Galta R, Rudd MF, Webb EL, Bridle H, Eisen T et al. Further observations on the relationship between the FGFR4 Gly388Arg polymorphism and lung cancer prognosis. Br J Cancer 2007; 96: 1904–1907.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Spinola M, Leoni V, Pignatiello C, Conti B, Ravagnani F, Pastorino U et al. Functional FGFR4 Gly388Arg polymorphism predicts prognosis in lung adenocarcinoma patients. J Clin Oncol 2005; 23: 7307–7311.

    Article  CAS  PubMed  Google Scholar 

  20. Stadler CR, Knyazev P, Bange J, Ullrich A . FGFR4 GLY388 isotype suppresses motility of MDA-MB-231 breast cancer cells by EDG-2 gene repression. Cell Signal 2006; 18: 783–794.

    Article  CAS  PubMed  Google Scholar 

  21. Thussbas C, Nahrig J, Streit S, Bange J, Kriner M, Kates R et al. FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer. J Clin Oncol 2006; 24: 3747–3755.

    Article  CAS  PubMed  Google Scholar 

  22. Stanford JL, Wicklund KG, McKnight B, Daling JR, Brawer MK . Vasectomy and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 1999; 8: 881–886.

    CAS  PubMed  Google Scholar 

  23. Agalliu I, Salinas CA, Hansten P, Ostrander EA, Stanford JL . Statin use and risk of prostate cancer: results from a population-based epidemiological study. Am J Epidemiol 2008; 168: 250–260.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Breslow NE, Day NE . Statistical Methods in Cancer Research. Volume I—The Analysis of Case-Control Studies. IARC Scientific Publications: Lyon, 1980, 360pp.

    Google Scholar 

  25. Cox DR . Regression models and life tables (with discussion). J Royal Stat Soc B 1972; 34: 187–220.

    Google Scholar 

  26. Desnoyers LR, Pai R, Ferrando RE, Hotzel K, Le T, Ross J et al. Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models. Oncogene 2008; 27: 85–97.

    Article  CAS  PubMed  Google Scholar 

  27. Jezequel P, Campion L, Joalland MP, Millour M, Dravet F, Classe JM et al. G388R mutation of the FGFR4 gene is not relevant to breast cancer prognosis. Br J Cancer 2004; 90: 189–193.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Spinola M, Leoni VP, Tanuma J, Pettinicchio A, Frattini M, Signoroni S et al. FGFR4 Gly388Arg polymorphism and prognosis of breast and colorectal cancer. Oncol Rep 2005; 14: 415–419.

    CAS  PubMed  Google Scholar 

  29. Rabbani SA, Xing RH . Role of urokinase (uPA) and its receptor (uPAR) in invasion and metastasis of hormone-dependent malignancies. Int J Oncol 1998; 12: 911–920.

    CAS  PubMed  Google Scholar 

  30. Sidenius N, Blasi F . The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy. Cancer Metastasis Rev 2003; 22: 205–222.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank all the men who participated in this study for their time, effort and cooperation. This work was supported by grants RO1 CA56678, RO1 CA82664, RO1 CA092579 and P50 CA97186 from the National Cancer Institute; additional support was provided by the Fred Hutchinson Cancer Research Center and the Intramural Program of the National Human Genome Research Institute.

Author information

Author notes

  1. L M FitzGerald and E Karlins: These authors contributed equally to this work.

Authors and Affiliations

  1. Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA

    L M FitzGerald, J S Koopmeiners & J L Stanford

  2. National Human Genome Research Institute, Cancer Genetics Branch, National Institutes of Health, Bethesda, MD, USA

    E Karlins, D M Karyadi, E M Kwon & E A Ostrander

  3. Department of Epidemiology, School of Public Health and Community Medicine, University of Washington, Seattle, WA, USA

    J L Stanford

Authors
  1. L M FitzGerald
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E Karlins
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D M Karyadi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. E M Kwon
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J S Koopmeiners
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J L Stanford
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. E A Ostrander
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to E A Ostrander.

Additional information

This study was conducted within the Epidemiology Program of the Fred Hutchinson Cancer Research Center, Seattle, WA, USA. Genotyping was performed in the Comparative Genomics Section of the National Human Genome Research Institute, NIH, Bethesda, MD, USA.

Rights and permissions

Reprints and permissions

About this article

Cite this article

FitzGerald, L., Karlins, E., Karyadi, D. et al. Association of FGFR4 genetic polymorphisms with prostate cancer risk and prognosis. Prostate Cancer Prostatic Dis 12, 192–197 (2009). https://doi.org/10.1038/pcan.2008.46

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/pcan.2008.46

Keywords

This article is cited by

Search

Advanced search

Quick links